Cargando…
Ambivalence about supervised injection facilities among community stakeholders
BACKGROUND: Community stakeholders express a range of opinions about supervised injection facilities (SIFs). We sought to identify reasons for ambivalence about SIFs amongst community stakeholders in two Canadian cities. FINDINGS: We used purposive sampling methods to recruit various stakeholder rep...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4546245/ https://www.ncbi.nlm.nih.gov/pubmed/26292715 http://dx.doi.org/10.1186/s12954-015-0060-3 |
_version_ | 1782386885843222528 |
---|---|
author | Strike, Carol Watson, Tara Marie Kolla, Gillian Penn, Rebecca Bayoumi, Ahmed M. |
author_facet | Strike, Carol Watson, Tara Marie Kolla, Gillian Penn, Rebecca Bayoumi, Ahmed M. |
author_sort | Strike, Carol |
collection | PubMed |
description | BACKGROUND: Community stakeholders express a range of opinions about supervised injection facilities (SIFs). We sought to identify reasons for ambivalence about SIFs amongst community stakeholders in two Canadian cities. FINDINGS: We used purposive sampling methods to recruit various stakeholder representatives (n = 141) for key informant interviews or focus group discussions. Data were analyzed using a thematic process. We identified seven reasons for ambivalence about SIFs: lack of personal knowledge of evidence about SIFs; concern that SIF goals are too narrow and the need for a comprehensive response to drug use; uncertainty that the community drug problem is large enough to warrant a SIF(s); the need to know more about the “right” places to locate a SIF(s) to avoid damaging communities or businesses; worry that a SIF(s) will renew problems that existed prior to gentrification; concern that resources for drug use prevention and treatment efforts will be diverted to pay for a SIF(s); and concern that SIF implementation must include evaluation, community consultation, and an explicit commitment to discontinue a SIF(s) in the event of adverse outcomes. CONCLUSIONS: Stakeholders desire evidence about potential SIF impacts relevant to local contexts and that addresses perceived potential harms. Stakeholders would also like to see SIFs situated within a comprehensive response to drug use. Future research should determine the relative importance of these concerns and optimal approaches to address them to help guide decision-making about SIFs. |
format | Online Article Text |
id | pubmed-4546245 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-45462452015-08-23 Ambivalence about supervised injection facilities among community stakeholders Strike, Carol Watson, Tara Marie Kolla, Gillian Penn, Rebecca Bayoumi, Ahmed M. Harm Reduct J Brief Report BACKGROUND: Community stakeholders express a range of opinions about supervised injection facilities (SIFs). We sought to identify reasons for ambivalence about SIFs amongst community stakeholders in two Canadian cities. FINDINGS: We used purposive sampling methods to recruit various stakeholder representatives (n = 141) for key informant interviews or focus group discussions. Data were analyzed using a thematic process. We identified seven reasons for ambivalence about SIFs: lack of personal knowledge of evidence about SIFs; concern that SIF goals are too narrow and the need for a comprehensive response to drug use; uncertainty that the community drug problem is large enough to warrant a SIF(s); the need to know more about the “right” places to locate a SIF(s) to avoid damaging communities or businesses; worry that a SIF(s) will renew problems that existed prior to gentrification; concern that resources for drug use prevention and treatment efforts will be diverted to pay for a SIF(s); and concern that SIF implementation must include evaluation, community consultation, and an explicit commitment to discontinue a SIF(s) in the event of adverse outcomes. CONCLUSIONS: Stakeholders desire evidence about potential SIF impacts relevant to local contexts and that addresses perceived potential harms. Stakeholders would also like to see SIFs situated within a comprehensive response to drug use. Future research should determine the relative importance of these concerns and optimal approaches to address them to help guide decision-making about SIFs. BioMed Central 2015-08-21 /pmc/articles/PMC4546245/ /pubmed/26292715 http://dx.doi.org/10.1186/s12954-015-0060-3 Text en © Strike et al. 2015 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Brief Report Strike, Carol Watson, Tara Marie Kolla, Gillian Penn, Rebecca Bayoumi, Ahmed M. Ambivalence about supervised injection facilities among community stakeholders |
title | Ambivalence about supervised injection facilities among community stakeholders |
title_full | Ambivalence about supervised injection facilities among community stakeholders |
title_fullStr | Ambivalence about supervised injection facilities among community stakeholders |
title_full_unstemmed | Ambivalence about supervised injection facilities among community stakeholders |
title_short | Ambivalence about supervised injection facilities among community stakeholders |
title_sort | ambivalence about supervised injection facilities among community stakeholders |
topic | Brief Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4546245/ https://www.ncbi.nlm.nih.gov/pubmed/26292715 http://dx.doi.org/10.1186/s12954-015-0060-3 |
work_keys_str_mv | AT strikecarol ambivalenceaboutsupervisedinjectionfacilitiesamongcommunitystakeholders AT watsontaramarie ambivalenceaboutsupervisedinjectionfacilitiesamongcommunitystakeholders AT kollagillian ambivalenceaboutsupervisedinjectionfacilitiesamongcommunitystakeholders AT pennrebecca ambivalenceaboutsupervisedinjectionfacilitiesamongcommunitystakeholders AT bayoumiahmedm ambivalenceaboutsupervisedinjectionfacilitiesamongcommunitystakeholders |